SOM Biotech, a clinical-stage drug discovery and development company based on a unique proprietary Artificial Intelligence platform (SOMAIPRO®), is pleased to announce that the recruitment of the Phase IIb clinical study with SOM3355 as a treatment for Huntington’s chorea has been completed.

After a a Phase IIa study where the patients confirmed the good safe profile and clinical benefit on choreic movements , SOM Biotech conducted a 12-weeks doubleblind, placebo-controlled dose-finding Phase IIb study, assessing the efficacy and safety of two dose regimens. Results are expected by the end of the year.

Click here to read the full press release.


0 تعليق

اترك تعليقاً

عنصر نائب للصورة الرمزية (Avatar)

لن يتم نشر عنوان بريدك الإلكتروني. الحقول الإلزامية مشار إليها بـ *

arArabic